| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 12.9 | 14.5 |
| Net income | -94.8 | -69.4 |
| EPS (diluted, $ a share) | $-0.42 | $-0.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -11.5% |
|---|
10-Q filed with the SEC, NASDAQ: OCUL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ocular Therapeutix, Inc: key numbers
- Share price
- $6.01Close, Nov 16
- Market cap
- $1.32B
- Shares outstanding
- 220.02MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ocular Therapeutix, Inc
All →Ocular Therapeutix Chief Business Officer Namrata Saroj Sells $232K of Stock
Namrata Saroj, Chief Business Officer, sold 35,370 shares of Ocular Therapeutix, Inc at $6.55 a share, worth $232K in total on Nov 5, 2026. Shares held after the trade: 220,522 (-13.8%).
- Value
- $232K
- Shares
- 35,370
- Price
- $6.55
- Role
- Chief Business Officer
- Holding change
- -13.8%
- Trade date
- Nov 5, 2026
Ocular Therapeutix Leadership Change
Ocular Therapeutix appointed Riad Sherif, M.D., to its Board of Directors as a Class I member, effective November 6, 2026. Dr. Sherif, currently the CEO of Oculis Holding AG and a former Alcon executive, received an initial equity grant of 88,000 stock options and 28,000 restricted stock units as part of his appointment.
- Counterparty
- Riad Sherif, M.D.
Ocular Therapeutix Financial Results
Ocular Therapeutix reported Q3 2026 financial results, highlighting a cash position of $530.6 million and an expected runway into 2028. The company remains on track to submit its NDA for AXPAXLI in wet AMD during Q4 2026 following a positive pre-NDA meeting with the FDA in September.
- Term
- Q3 2026
“2026 has been a transformational year for Ocular Therapeutix and we are in a strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the 505(b)(2) regulatory pathway. Frequent injections define today’s wet AMD treatment experience, and we believe AXPAXLI has the transformative potential to drastically reduce the burden on patients and caregivers.”
Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix
Ocular Therapeutix Leadership Change
Sanjay Nayak, M.B.B.S., Ph.D., notified Ocular Therapeutix of his resignation as Chief Strategy Officer, effective October 16, 2026. Dr. Nayak is leaving the company to become the Chief Executive Officer of a privately-held company.
Ocular Therapeutix CLO Todd Anderman Sells $87.4K of Stock
Todd Anderman, CLO, sold 11,984 shares of Ocular Therapeutix, Inc at $7.29 a share, worth $87.4K in total on Oct 8, 2026. Shares held after the trade: 140,484 (-7.9%).
- Value
- $87.4K
- Shares
- 11,984
- Price
- $7.29
- Role
- CLO
- Holding change
- -7.9%
- Trade date
- Oct 8, 2026
Ocular Therapeutix Chief Development Officer Peter Kaiser Sells $70.4K of Stock
Peter Kaiser, Chief Development Officer, sold 9,990 shares of Ocular Therapeutix, Inc at $7.05 a share, worth $70.4K in total on Oct 2, 2026. Shares held after the trade: 254,388 (-3.8%).
- Value
- $70.4K
- Shares
- 9,990
- Price
- $7.05
- Role
- Chief Development Officer
- Holding change
- -3.8%
- Trade date
- Oct 2, 2026